In-hospital and nine-month outcomes among patients with coronary lesions involving a side branch and treated with bare metal stents.

Side branch jailing: should we worry? Catheter Cardiovasc Interv (2010) 0.75

Stenting versus endarterectomy for treatment of carotid-artery stenosis. N Engl J Med (2010) 17.57

Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med (2003) 13.29

Protected carotid-artery stenting versus endarterectomy in high-risk patients. N Engl J Med (2004) 12.58

A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med (2004) 11.86

Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med (2014) 10.54

Stenting and medical therapy for atherosclerotic renal-artery stenosis. N Engl J Med (2013) 8.91

Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation (2011) 6.36

Transcatheter aortic-valve replacement with a self-expanding prosthesis. N Engl J Med (2014) 5.88

Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med (2007) 5.77

Comparative effectiveness of revascularization strategies. N Engl J Med (2012) 5.49

Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med (2007) 5.37

Supervised exercise versus primary stenting for claudication resulting from aortoiliac peripheral artery disease: six-month outcomes from the claudication: exercise versus endoluminal revascularization (CLEVER) study. Circulation (2011) 4.95

Long-term results of carotid stenting versus endarterectomy in high-risk patients. N Engl J Med (2008) 4.72

Standardized endpoint definitions for Transcatheter Aortic Valve Implantation clinical trials: a consensus report from the Valve Academic Research Consortium. J Am Coll Cardiol (2011) 3.37

Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med (2010) 3.27

One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation (2004) 3.23

Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. JAMA (2005) 3.06

Nonemergency PCI at hospitals with or without on-site cardiac surgery. N Engl J Med (2013) 2.98

Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease. N Engl J Med (2015) 2.97

A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med (2007) 2.91

Zotarolimus-eluting peripheral stents for the treatment of erectile dysfunction in subjects with suboptimal response to phosphodiesterase-5 inhibitors. J Am Coll Cardiol (2012) 2.85

Carotid artery stenting vs carotid endarterectomy: meta-analysis and diversity-adjusted trial sequential analysis of randomized trials. Arch Neurol (2010) 2.83

The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol (2004) 2.78

Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. J Am Coll Cardiol (2012) 2.78

Hospital delays in reperfusion for ST-elevation myocardial infarction: implications when selecting a reperfusion strategy. Circulation (2006) 2.72

Outcomes with various drug eluting or bare metal stents in patients with diabetes mellitus: mixed treatment comparison analysis of 22,844 patient years of follow-up from randomised trials. BMJ (2012) 2.66

Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. JAMA (2008) 2.59

Angiographic surrogate end points in drug-eluting stent trials: a systematic evaluation based on individual patient data from 11 randomized, controlled trials. J Am Coll Cardiol (2008) 2.54

Randomized trial of a distal embolic protection device during percutaneous intervention of saphenous vein aorto-coronary bypass grafts. Circulation (2002) 2.53

Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial. Circulation (2009) 2.39

Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation (2004) 2.35

The Carotid Revascularization Endarterectomy versus Stenting Trial: credentialing of interventionalists and final results of lead-in phase. J Stroke Cerebrovasc Dis (2010) 2.35

Impact of post-intervention minimal stent area on 9-month follow-up patency of paclitaxel-eluting stents: an integrated intravascular ultrasound analysis from the TAXUS IV, V, and VI and TAXUS ATLAS Workhorse, Long Lesion, and Direct Stent Trials. JACC Cardiovasc Interv (2009) 2.12

Standardized endpoint definitions for transcatheter aortic valve implantation clinical trials: a consensus report from the Valve Academic Research Consortium. Eur Heart J (2011) 2.11

Troponin criteria for myocardial infarction after percutaneous coronary intervention. Arch Intern Med (2012) 2.09

Cost-effectiveness of distal embolic protection for patients undergoing percutaneous intervention of saphenous vein bypass grafts: results from the SAFER trial. J Am Coll Cardiol (2004) 2.05

Effect of endothelial shear stress on the progression of coronary artery disease, vascular remodeling, and in-stent restenosis in humans: in vivo 6-month follow-up study. Circulation (2003) 2.04

Paclitaxel-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the TAXUS V ISR randomized trial. JAMA (2006) 2.03

Prevalence and prognostic significance of preprocedural cardiac troponin elevation among patients with stable coronary artery disease undergoing percutaneous coronary intervention: results from the evaluation of drug eluting stents and ischemic events registry. Circulation (2008) 2.01

Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent or bare metal stent placement for the treatment of coronary artery lesions. Am Heart J (2010) 2.00

Clinical efficacy of polymer-based paclitaxel-eluting stents in the treatment of complex, long coronary artery lesions from a multicenter, randomized trial: support for the use of drug-eluting stents in contemporary clinical practice. Circulation (2005) 2.00

Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. J Thorac Cardiovasc Surg (2012) 1.99

No-reflow is an independent predictor of death and myocardial infarction after percutaneous coronary intervention. Am Heart J (2003) 1.87

A randomized comparison of the Endeavor zotarolimus-eluting stent versus the TAXUS paclitaxel-eluting stent in de novo native coronary lesions 12-month outcomes from the ENDEAVOR IV trial. J Am Coll Cardiol (2010) 1.80

Myocardial infarction after carotid stenting and endarterectomy: results from the carotid revascularization endarterectomy versus stenting trial. Circulation (2011) 1.78

Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents. 5-year follow-up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions). JACC Cardiovasc Interv (2011) 1.75

Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document (VARC-2). Eur J Cardiothorac Surg (2012) 1.74

Recommendations for successful training on methods of delivery of biologics for cardiac regeneration: a report of the International Society for Cardiovascular Translational Research. JACC Cardiovasc Interv (2010) 1.74

Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. Eur Heart J (2012) 1.72

Carotid artery stenting is associated with increased complications in octogenarians: 30-day stroke and death rates in the CREST lead-in phase. J Vasc Surg (2004) 1.71

Clinical and angiographic results with the next-generation resolute stent system: a prospective, multicenter, first-in-human trial. JACC Cardiovasc Interv (2009) 1.70

Randomized comparison of everolimus- and paclitaxel-eluting stents. 2-year follow-up from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) IV trial. J Am Coll Cardiol (2011) 1.69

Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials. J Am Coll Cardiol (2002) 1.62

Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial. Circulation (2006) 1.62

Incidence and predictors of late total occlusion following coronary stenting. Catheter Cardiovasc Interv (2003) 1.61

Saphenous vein graft stenting and major adverse cardiac events: a predictive model derived from a pooled analysis of 3958 patients. Circulation (2008) 1.59

A decade of improvement in the clinical outcomes of percutaneous coronary intervention for multivessel coronary artery disease. Circulation (2002) 1.58

Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial. J Am Coll Cardiol (2006) 1.56

The truth and consequences of the COURAGE trial. J Am Coll Cardiol (2007) 1.55

The Nitinol SMART stent vs Wallstent for suboptimal iliac artery angioplasty: CRISP-US trial results. J Vasc Interv Radiol (2004) 1.55

Five-year clinical follow-up after intracoronary radiation: results of a randomized clinical trial. Circulation (2002) 1.55

Treatment of left anterior descending coronary artery disease with sirolimus-eluting stents. Circulation (2004) 1.54

Sirolimus-eluting stent for treatment of complex in-stent restenosis: the first clinical experience. J Am Coll Cardiol (2003) 1.53

Periprocedural myocardial infarction in a randomized trial of everolimus-eluting and Paclitaxel-eluting coronary stents: frequency and impact on mortality according to historic versus universal definitions. Circ Cardiovasc Interv (2012) 1.52

Differential mortality risk of postprocedural creatine kinase-MB elevation following successful versus unsuccessful stent procedures. J Am Coll Cardiol (2004) 1.52

In-stent restenosis and remote coronary lesion progression are coupled in cardiac transplant vasculopathy but not in native coronary artery disease. J Am Coll Cardiol (2006) 1.52

Induction of mild systemic hypothermia with endovascular cooling during primary percutaneous coronary intervention for acute myocardial infarction. J Am Coll Cardiol (2002) 1.51

Optimizing rotational atherectomy in high-risk percutaneous coronary interventions: insights from the PROTECT ΙΙ study. Catheter Cardiovasc Interv (2013) 1.50

TAXUS VI 2-year follow-up: randomized comparison of polymer-based paclitaxel-eluting with bare metal stents for treatment of long, complex lesions. Eur Heart J (2007) 1.50

Prediction of long-term mortality after percutaneous coronary intervention in older adults: results from the National Cardiovascular Data Registry. Circulation (2012) 1.50

Experience induces structural and biochemical changes in the adult primate brain. Proc Natl Acad Sci U S A (2005) 1.47

A randomized, controlled, multicenter trial to evaluate the safety and efficacy of zotarolimus- versus paclitaxel-eluting stents in de novo occlusive lesions in coronary arteries The ZoMaxx I trial. JACC Cardiovasc Interv (2008) 1.47

Repeat revascularization after contemporary percutaneous coronary intervention: an evaluation of staged, target lesion, and other unplanned revascularization procedures during the first year. Circ Cardiovasc Interv (2012) 1.46

The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part I: Pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease). Circulation (2006) 1.46

Persistent inhibition of neointimal hyperplasia after sirolimus-eluting stent implantation: long-term (up to 2 years) clinical, angiographic, and intravascular ultrasound follow-up. Circulation (2002) 1.46

An integrated TAXUS IV, V, and VI intravascular ultrasound analysis of the predictors of edge restenosis after bare metal or paclitaxel-eluting stents. Am J Cardiol (2008) 1.44

Stent thrombosis after successful sirolimus-eluting stent implantation. Circulation (2004) 1.43

Claudication: exercise vs endoluminal revascularization (CLEVER) study update. J Vasc Surg (2009) 1.43

2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards). J Am Coll Cardiol (2014) 1.43

High-frequency vibration for the recanalization of guidewire refractory chronic total coronary occlusions. Catheter Cardiovasc Interv (2008) 1.42

Platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment during saphenous vein graft stenting: differential effects after randomization to occlusion or filter-based embolic protection. Eur Heart J (2006) 1.42

Two-year clinical outcomes after paclitaxel-eluting stent or brachytherapy treatment for bare metal stent restenosis: the TAXUS V ISR trial. Eur Heart J (2008) 1.41

2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards). J Nucl Cardiol (2015) 1.41

Proper patient selection yields significant and sustained reduction in systolic blood pressure following renal artery stenting in patients with uncontrolled hypertension: long-term results from the HERCULES trial. J Clin Hypertens (Greenwich) (2014) 1.40

Safety and efficacy metrics for primary nitinol stenting in femoropopliteal occlusive disease: a meta-analysis and critical examination of current methodologies. Catheter Cardiovasc Interv (2014) 1.40

Angiographic outcome after intracoronary X-Sizer helical atherectomy and thrombectomy: first use in humans. Catheter Cardiovasc Interv (2002) 1.39

Five-year clinical follow-up after implantation of the Endeavor zotarolimus-eluting stent: ENDEAVOR I, first-in-human study. Catheter Cardiovasc Interv (2009) 1.39

Multivessel drug-eluting stenting and impact of diabetes mellitus--a report from the EVENT registry. Catheter Cardiovasc Interv (2009) 1.39